HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial.

Antonio Llombart José Pérez-García Fara Brasó-Maristany Laia Paré Guillermo Villacampa Maria Gion Peter Schmid Marco Colleoni Manuel Ruiz Borrego Patricia Galván Joel S Parker Wesley Buckingham Charles M Perou Patricia Villagrasa Jose Antonio Guerrero Miguel Sampayo Mario Mancino Aleix Prat Javier Cortes

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

HER2DX predicts pCR in the context of neoadjuvant HP-based therapy, regardless of chemotherapy addition, and might identify patients at higher risk of recurrence among patients with residual disease.

Keyphrases

early breast cancer
locally advanced
epidermal growth factor receptor
rectal cancer
metastatic breast cancer
lymph node
high throughput
squamous cell carcinoma
open label
clinical trial
radiation therapy
dna methylation
tyrosine kinase
placebo controlled
chemotherapy induced